Want to know if your doctor is receiving free lunches and other perks from Pfizer, GSK or some other huge player in the pharmaceuticals or medical device business? Starting in Sept. 2014, that information will be made available to consumers courtesy of the federal government. [More]
Govt. To Publish Data On What Drug & Device Makers Pay To Individual Doctors & Hospitals
By February 1, 2013
DOJ Alleges Glaxo Paid Dr. Drew $275K To Talk Sexy About Wellbutrin
By July 3, 2012
Yesterday, pharma biggie GlaxoSmithKline settled for $3 billion with the Justice Dept. over a wide range of fraud-related allegations. Among all the documents involved in the case are claims by the DOJ that GSK paid TV/Radio personality Dr. Drew Pinsky a pile of cash to talk up off-label uses of the company’s antidepressant Wellbutrin, including a purported tie to causing multiple orgasms in females. [More]
GlaxoSmithKline Pleads Guilty & Will Pay U.S. $3 Billion To Resolve Fraud Allegations
By July 2, 2012
In the largest health care fraud settlement in U.S. history, prescription drug giant GlaxoSmithKline is set to plead guilty and pay $3 billion to the U.S. government. The settlement will resolve federal criminal and civil inquiries about things ranging from the company’s illegal promotion of some of its products to its failure to report safety data and alleged false price reporting. [More]
GSK Sued For Fraudulently Delaying Generic Version Of Wellbutrin
By May 14, 2008
A class action lawsuit has been filed accusing GlaxoSmithKline of lying to the Patent office and dickering with fake patent litigation against generic drug makers to fraudulently stymie generic versions of Wellbutrin from hitting the market. The lawsuit applies to people who directly bought Wellbutrin from GSK in 100 or 150mg hits between Jan 24, 2002 and June 30, 2006. Obviously, the long GSK could keep a generic version of their drug off the market, the more money they could make. People interested in joining could probably contact the firm of Roda and Nast, lead plaintiff team, for more information.
Glaxo Buys Aging Retardation Drug Company
By April 24, 2008
GlaxoSmithKline is buying a U.S. biotechnology company that is researching resveratrol, the chemical compound found in red wine that may retard the aging process. The CEO of the company says that “drugs that mimic resveratrol, by activating enzymes called sirtuins, could ‘treat in a safe, natural new way, many of the major killers of western society.’” We can’t wait to see the commercials that GSK puts out for this one.
Paxil Unafraid to Demonstrate Bling in ’98 Memo
By July 20, 2006
You may recall Paxil as the inspiration for several Law & Order episodes. In 2004, NY Attorney General began proceedings against Paxil makers GlaxoSmithKline after the company suppressed five internal studies between 1998 and 2002 revealing links between the drug and incidences of suicide among its users, especially children and young adults.
